Publicaciones en las que colabora con Marina Cortijo Gutierrez (12)

2024

  1. Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. Lentiviral vectors for inducible, transactivator-free advanced therapy medicinal products: Application to CAR-T cells

    Molecular Therapy - Nucleic Acids, Vol. 32, pp. 322-339

2022

  1. Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma

    Frontiers in Immunology, Vol. 13

  2. Erratum: Physiological lentiviral vectors for the generation of improved CAR-T cells (Molecular Therapy - Oncolytics (2022) 25 (335–349), (S2372770522000687), (10.1016/j.omto.2022.05.003))

    Molecular Therapy - Oncolytics

  3. Physiological lentiviral vectors for the generation of improved CAR-T cells

    Molecular Therapy - Oncolytics, Vol. 25, pp. 335-349

2021

  1. Improved functionality of integration-deficient lentiviral vectors (IDLVs) by the inclusion of IS2 protein docks

    Pharmaceutics, Vol. 13, Núm. 8

2020

  1. Development of Cellular Models to Study Efficiency and Safety of Gene Edition by Homologous Directed Recombination Using the CRISPR/Cas9 System

    Cells, Vol. 9, Núm. 6

  2. Exosome: A new player in translational nanomedicine

    Journal of Clinical Medicine, Vol. 9, Núm. 8, pp. 1-27

  3. Externally-Controlled Systems for Immunotherapy: From Bench to Bedside

    Frontiers in Immunology, Vol. 11

  4. Genome-edited adult stem cells: Next-generation advanced therapy medicinal products

    Stem Cells Translational Medicine, Vol. 9, Núm. 6, pp. 674-685

  5. Using Gene Editing Approaches to Fine-Tune the Immune System

    Frontiers in Immunology, Vol. 11

2018

  1. The IS2 Element Improves Transcription Efficiency of Integration-Deficient Lentiviral Vector Episomes

    Molecular Therapy - Nucleic Acids, Vol. 13, pp. 16-28